Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma: A case report and review of the literature.

Abstract

RATIONALE:

Anlotinib has been proved to be effective in advanced refractory non-small cell lung cancer.

PATIENT CONCERNS:

A 47-year-old female non-smoker was admitted due to persistent chest tightness for a month.

DIAGNOSES:

Epidermal growth factor receptor (EGFR) wild-type advanced primary lung adenocarcinoma without brain or bone metastasis.

INTERVENTIONS:

The patient failed 2 lines of pemetrexed/docetaxel plus carboplatin and third-line erlotinib. Fourth-line anlotinib was administered thereafter.

OUTCOMES:

The pulmonary lesions showed partial remission 5 months after anlotinib monotherapy. The patient demonstrated a progression-free survival of more than 7 months and an overall survival of >12 months. The adverse events including hypertension and fatigue were well-tolerated.

LESSONS:

Salvage anlotinib might be a reasonable choice in EGFR wild-type lung adenocarcinoma after failure of chemotherapy. Further well-designed trials are warranted to verify this occasional finding.

• Authors: Lei Liu, Xiang Wang, Wen-Bin Wu, Miao Zhang
• Journal: Medicine (Medicine (Baltimore)) Vol. 99 Issue 41 Pg. e22707 (Oct 09 2020) ISSN: 1536-5964 [Electronic] United States
• PMID: 33031343 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Indoles
• Quinolines
• anlotinib

Topics

• Adenocarcinoma (drug therapy, genetics)
• Female
• Genes, erbB-1
• Humans
• Indoles (therapeutic use)
• Lung Neoplasms (drug therapy, genetics)
• Middle Aged
• Quinolines (therapeutic use)
• Salvage Therapy